About T1D
T1D is a debilitating disease occurring in millions of patients globally, with rising incidences each year, where despite advancements in therapy the life expectancy remains lower than the general population. Diabetes is an autoimmune disease where self-reactive T lymphocytes selectively attack and destroy insulin-producing β cells lodged within the pancreas, leaving the patient unable to maintain glucose homeostasis. To date, T1D cannot be cured, and glucose homeostasis can only be maintained using daily insulin injections. In addition, secondary complications of the current therapy are considerable and can lead to significant morbidity and mortality. Using Nimvec™ AM510 Amarna intends to restore the immune tolerance to insulin and potentially cure the patients.
About Nimvec™ AM510
The development of AM510 is based on our proprietary Nimvec™ platform, which has demonstrated exceptional promise in preclinical studies. Unlike other gene therapies that induce a strong immune response, limiting the possibility for repeat dosing and efficacy, Nimvec™ does not trigger such immune responses. Instead, it moderates the immune system to induce tolerance, making it an ideal vehicle for our therapeutic approach. Our preclinical data with Nimvec™ AM510 showcases its protective effects in delaying the onset of hyperglycemia and preventing the development of T1DM in relevant animal models.
About Nimvec Therapeutics
Amarna Therapeutics is at the forefront of developing groundbreaking immune-modulating gene therapies for rare and prevalent autoimmune diseases and genetic diseases. The company’s proprietary Nimvec™ platform is designed to deliver transformative treatments with exceptional promise in preclinical studies. Amarna is committed to pioneering treatments for Type 1 Diabetes Mellitus and enhancing patient outcomes.
About NorthX Biologics
NorthX Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO), has expertise in producing cell and gene therapies, proteins, vaccines, other advanced biologics. With two sites in Sweden and headquartered in Matfors, the team has been manufacturing biologics to GMP standards since 1992. In 2021 NorthX was designated an innovation hub for advanced therapies and vaccines and has the ambition to become a leading cell and gene therapy manufacturer and partner for innovative drug development companies.
More information on www.amarnatherapeutics.com ; www.nxbio.com
